AstraZeneca bid to expand lung cancer drug's use boosted by trial data

A study of an AstraZeneca lung cancer treatment was recently stopped two years early because independent trial advisors concluded the drug, called Tagrisso, had already clearly shown a benefit over placebo. On Thursday, doctors get to see why. Results show Tagrisso reduced the risk of disease progression following surgery by 80%, a result the lead study investigator called a "home run."